Dossier assessment
Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Advanced (unresectable or metastatic) melanoma in adolescents aged between 12 and 18 years
Inadequate transfer of results from study with adults; added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.
Project details
- Project no.
- A18-12
- Commission
- Commission awarded on 15.02.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed